# AgonOx

Source: https://onco.cc/companies/agonox/  
OnCo record `agonox` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AgonOx is a Portland company growing a patient's own tumour-fighting immune cells for re-infusion, selecting only the fraction that recognises the tumour. Its therapy, AGX-148, is in an early trial in solid tumours.

## Summary

AgonOx, Inc. develops tumour-infiltrating lymphocyte (TIL) therapy that isolates and expands the CD39-positive, CD103-positive subset of a patient's CD8 TIL, which the company describes as the tumour-reactive fraction. Its lead programme AGX-148 is in phase 1 in solid tumours, with further cell therapy programmes in IND-enabling studies. AgonOx sponsors NCT05902520, a phase 1 trial of these CD8 TIL in adults with solid tumours, which ClinicalTrials.gov lists as active and not recruiting. A 2026 National Cancer Institute SBIR award funds enriching and expanding tumour-reactive CD8 T cells to treat breast cancer.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: AgonOx, Inc.
- HQ: Portland, OR
- Type: cell-therapy
- Website: https://www.agonox.com/

## Notes

- Company website, the NIH RePORTER record and the ClinicalTrials.gov record for NCT05902520 read on 4 November 2026. NCT05902520 is not yet a trial record in OnCo.

## Sources

- Official website: https://www.agonox.com/
- NIH RePORTER: award 1R44CA314796-01: https://reporter.nih.gov/project-details/11408886
- ClinicalTrials.gov: CD8 TIL in solid tumours (NCT05902520): https://clinicaltrials.gov/study/NCT05902520

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [TIL therapy](https://onco.cc/technologies/til-therapy/)
- drugs: [AGX-148](https://onco.cc/drugs/agx-148/)

---
JSON: https://onco.cc/api/v1/entities/agonox.json